Previously, multivariate analyses revealed that patients with IDH1-mutant glioblastoma, now classified as grade 4 astrocytoma, and MGMT promoter methylation exhibited improved survival compared with patients having one or neither of these molecular alterations [46,47]. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).